Abstract
PURPOSE: Moxifloxacin 8-methoxy-quinolone has an excellent in virto activity against common gram positive, gram negative and intracellular respiratory tract pathogens. Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is characterized by increase in cough and worsening of dyspnoea due to, in some cases, bacterial infection. There is always a need to develop first line antimicrobial agents that cover major respiratory pathogens, with low potential to select for resistance, favorable safety and tolerability profiles, and convenient dosing regimen. The purpose of this study was to evaluate the outcome of treating AECOPD patients empirically with 400 mg moxifloxacin single oral dose for 5 and 10 days.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call